Stomach cancer (credit: canva)
Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).
A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:
1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.
2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.
3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.
4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.
5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding
There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.
Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.
1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.
2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.
3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.
He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.
Credit: iStock
For the first time, starting July 1, people in the US will be able to access GLP-1 drugs for weight loss through a new pilot program offered by the federal health insurance program Medicare.
Until now, Medicare covered GLP-1 medications such as Ozempic only for certain conditions like diabetes, but not for weight loss.
The new 18-month Medicare GLP-1 Bridge Program, which will run till the end of 2027, aims to make these high-cost weight-loss medications more accessible to eligible beneficiaries.
According to a KFF analysis of 2023 Part D enrollment data, an estimated 3.8 million Medicare beneficiaries could qualify for the program.
More than 70 per cent of adults in the United States are considered to have obesity or screen as overweight. Studies have proven that GLP-1s are an effective tool in weight reduction, as well as improving other markers of good health, such as blood pressure, lipid profiles, and blood sugar levels.
Eligible beneficiaries will be able to access the following GLP-1 weight-loss medications:
The medications will be covered only when prescribed for weight management and when beneficiaries meet the program's medical eligibility criteria.
The program is available only to certain members of Medicare Part D prescription drug plans who want to lose excess weight and maintain weight loss.
Although the program operates outside standard Medicare Part D coverage, beneficiaries can participate only if they are enrolled in:
People enrolled in certain less common Medicare plans, including the Program of All-inclusive Care for the Elderly (PACE), may also qualify if they also have a stand-alone Part D plan, Washington Post reported.
According to the Centers for Medicare & Medicaid Services (CMS), most of Medicare's approximately 57 million Part D enrollees are in eligible plans.
However, coverage is not automatic. Providers and pharmacists will identify eligible patients, submit the required forms and obtain prior authorization before treatment can begin. Claims, prior authorization requests and pharmacy payments will be handled by Humana, while Part D plans will not be involved in the process.
Eligible beneficiaries will pay a $50 monthly copay for the covered medications.
However, because the program operates outside Medicare Part D coverage:
The pilot program is temporary and is scheduled to end in December 2027, unless it is extended.
"It's certainly good news for Medicare beneficiaries who have been essentially shut out of the market for GLP-1s for weight loss if they wanted to use insurance coverage. However, it is a temporary program. It is not a permanent change in Medicare coverage," said Juliette Cubanski, Vice President and Director of Medicare Policy at KFF.
If the program is not extended, beneficiaries who rely on the medications may have to pay higher out-of-pocket prices or discontinue treatment beginning in January 2028, which experts said could lead to weight regain based on current GLP-1 therapies, the Post reported.
Credit: AI generated image
Heart failure (HF) remains a major global health challenge, affecting more than 64 million adults worldwide.
To improve how the condition is prevented, diagnosed and managed, leading cardiovascular organizations, including the American Heart Association (AHA) and the American College of Cardiology (ACC), have released the "Second Universal Definition of Heart Failure."
The updated definition addresses changes in disease manifestations, diagnostic strategies and the understanding of heart failure's underlying biology. It also aims to establish a unified framework for clinicians, researchers, health systems and policymakers worldwide.
Published on behalf of the ACC, AHA, European Society of Cardiology (ESC) and World Heart Federation (WHF), in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the ESC and the Japanese Heart Failure Society (JHFS), the document updates the First Universal Definition of Heart Failure, released in 2021. It has been published simultaneously in Circulation, Journal of the American College of Cardiology (JACC), European Heart Journal and Global Heart.
The prevalence of heart failure continues to rise due to ageing populations and increasing rates of obesity, Type 2 diabetes and high blood pressure.
To better address this growing burden, the new framework introduces several important changes.
The revised definition provides a common framework for clinicians, researchers, health systems and policymakers worldwide, helping standardize diagnosis, strengthen research and support more personalized care.
The consensus document will also serve as the foundation for the upcoming American Heart Association/American College of Cardiology Heart Failure Guideline, expected to be published in late 2027.
"Heart failure remains a major challenge that continues to grow globally, and inconsistencies in how it is defined have limited progress in research and treatment. This updated definition provides a clearer, more consistent framework to help clinicians identify risk earlier and guide more personalized treatment approaches that can help improve patient outcomes worldwide," said Mary Norine Walsh, co-chair of the consensus document.
"The new framework recognizes that heart failure is not a static condition. By focusing on stages of disease, underlying causes and disease trajectories—including improvement, remission and recovery—we can better tailor care and advance prevention efforts," she added.
Credit: iStock
Amid concerns over the ongoing Ebola outbreak in neighboring Democratic Republic of Congo, Sudan has declared a new cholera outbreak, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus announced.
The outbreak has been reported in West Kordofan state.
As of June 20, Sudan's State Ministry of Health had reported 838 suspected cholera cases, seven confirmed cases and 117 deaths.
Conflict Hampering Response
"The outbreak is unfolding amid the continued disruption of health services caused by conflict. Population displacement is making access to essential health care even more difficult. At the same time, insecurity and access constraints continue to delay the deployment of response teams and delivery of medical supplies and humanitarian assistance," Tedros said.
He added that WHO is coordinating the response with partners by scaling up cholera treatment centers and oral rehydration points, delivering cholera kits, installing handwashing stations, training chlorinators, hygiene promoters and health workers, and supporting community health education.
Also Read: Ebola Outbreak Spreads To Fourth Province In DR Congo As Cases Rise To 1,274
Since the conflict began in 2023, Sudan has declared three waves of cholera outbreaks, with the most recent before this one occurring in January 2025 in White Nile State.
The latest announcement comes less than four months after Sudan declared the end of a cholera outbreak that began in July 2024. That outbreak spread across all 18 states, infected more than 124,000 people and claimed 3,573 lives.
According to the health ministry, the outbreak was largely linked to contaminated drinking water after the city's water supply facility was damaged in an attack by paramilitary forces.
Read More: WHO Warns of 70% Risk of Ebola Spread to South Sudan
The combination of conflict, displacement, damaged infrastructure and recurring disease outbreaks has placed millions at risk, with children under five among the most vulnerable.
According to the UNICEF, Sudan's healthcare system is also on the verge of collapse, leaving millions of children at greater risk of infectious diseases. Continued displacement has forced families into overcrowded settlements with limited access to clean water, sanitation and healthcare, creating ideal conditions for cholera and other waterborne diseases to spread.
The outbreaks have been intensified by multiple factors. The war has displaced millions, forcing many into camps with poor sanitation. Health centers, schools and water facilities have been damaged or repurposed as shelters.
Seasonal rains and flooding have further contaminated water sources, accelerating disease transmission.
According to the Centers for Disease Control and Prevention (CDC), it is caused by the bacterium Vibrio cholerae. This can be transmitted through drinking water or eating food that contains the bacteria. While most people who get cholera don't get sick, it can cause life-threatening diarrhea and vomiting.
CDC notes that each year, 1.3 to 4 million people around the world get cholera. Among them, 21,000 to 143,000 people die.
The common symptoms include:
People who live in areas with unsafe drinking water, poor sanitation, and inadequate hygiene are at the highest risk of getting cholera. The disease can spread quickly in areas where sewage and drinking water are not adequately treated. It can also live in brackish water, which is slightly salty, or in coastal water. Thus, eating raw shellfish can also cause cholera.
© 2024 Bennett, Coleman & Company Limited